| 1478 |
National Cancer Institute |
Html |
en |
Skin Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of skin cancer. |
| treatment | 0.409923 |
| metastatic basal cell | 0.400394 |
| subsequent basal cell | 0.391984 |
| Skin Cancer Prevention | 0.365074 |
| Arch Dermatol | 0.471327 |
| photodynamic therapy | 0.399886 |
| sun-exposed skin | 0.375699 |
| skin cancers | 0.433811 |
| primary skin cancers | 0.370681 |
| uncomplicated basal cell | 0.398522 |
| basal-cell carcinoma | 0.373761 |
| PUBMED Abstract | 0.376972 |
| Mohs micrographic surgery | 0.406259 |
| Invest Dermatol | 0.363857 |
| prior skin cancer | 0.363746 |
| multiple basal cell | 0.397256 |
| nonmelanoma skin cancers | 0.400983 |
| recurrence rates | 0.396208 |
| Dermatol Surg Oncol | 0.421496 |
| periocular basal cell | 0.39808 |
| BCC | 0.370104 |
| Abstract | 0.389392 |
| main skin cancer | 0.382703 |
| basal cell nevus | 0.404293 |
|
| squamous cell carcinomas | 0.385705 |
| eyelid addresses carcinomas | 0.365517 |
| non-eyelid skin cancers | 0.367643 |
| surgical excision | 0.369879 |
| Br J Dermatol | 0.407426 |
| cosmetic results | 0.379562 |
| superficial basal cell | 0.487048 |
| skin cancer awareness | 0.383438 |
| basal cell carcinomas | 0.527823 |
| nodular skin BCCs | 0.369486 |
| nodular basal cell | 0.432753 |
| nonmelanoma skin cancers. | 0.373768 |
| nevoid Basal cell | 0.396437 |
| primary superficial basal | 0.391239 |
| radiation therapy | 0.475907 |
| nonmelanoma skin cancer | 0.483068 |
| basal cell carcinoma | 0.980145 |
| regional lymph nodes | 0.369237 |
| radiation therapy treatment | 0.376744 |
| longstanding skin ulcers | 0.361677 |
| et al. | 0.442813 |
| Acad Dermatol | 0.422124 |
| squamous cell carcinoma | 0.41423 |
|
CLICK HERE |
| 1688 |
National Cancer Institute |
Html |
en |
Cannabis and Cannabinoids (PDQ®)–Patient Version |
Expert-reviewed information summary about the use of Cannabis and cannabinoids in the treatment of cancer-related side effects, such as nausea and vomiting. |
| cancer treatment | 0.54874 |
| PDQ Cannabis | 0.53541 |
| PDQ cancer information | 0.561631 |
| Cancer Complementary | 0.483651 |
| cancer therapy | 0.493942 |
| clinical trials | 0.738523 |
| cannabinoid receptors | 0.573547 |
| advanced cancer patients | 0.489779 |
| U.S. Food | 0.49892 |
| cancer information summary | 0.529639 |
| National Institutes | 0.485607 |
| alternative cancer therapies | 0.482187 |
| clinical trial | 0.556349 |
| cancer therapies | 0.496308 |
| patients | 0.580973 |
| cancer patients | 0.559766 |
| Cannabis users | 0.54158 |
| Investigational New Drug | 0.490753 |
| NCI PDQ cancer | 0.493719 |
| cancer information database | 0.48226 |
| effects | 0.498728 |
| cannabinoids | 0.769857 |
| main active cannabinoid | 0.509915 |
| treatment | 0.563891 |
|
| breast cancer cells | 0.497802 |
| Cannabis plant extract | 0.540785 |
| United States | 0.581783 |
| Cannabis plant | 0.559258 |
| Complementary Therapies Editorial | 0.487662 |
| Drug Administration | 0.596753 |
| Cancer Information Specialist | 0.479354 |
| cancer cells | 0.516435 |
| Cancer Information Service | 0.529301 |
| Cannabis extract | 0.551963 |
| National Cancer Institute | 0.60295 |
| studies | 0.507275 |
| alternative medicine | 0.50524 |
| pain relief | 0.516491 |
| advanced cancer | 0.497262 |
| approved research settings | 0.478938 |
| cannabis | 0.903862 |
| chemotherapy-related nausea | 0.514076 |
| cancer cell death | 0.500487 |
| medicinal Cannabis | 0.540165 |
| cancer clinical trials | 0.488981 |
| alternative therapies | 0.483937 |
| cancer information summaries | 0.482387 |
| cancer | 0.807964 |
|
CLICK HERE |
| 1798 |
National Cancer Institute |
Html |
es |
Aflicción, duelo y manejo de la pérdida (PDQ®)–Versión para pacientes |
Informe revisado por expertos acerca de la aflicción, el duelo y los sentimientos de pérdida de los sobrevivientes de alguien que murió de cáncer. Se trata también la aflicción en los niños. |
| cope with grief | 0.320516 |
| Helping Children | 0.322023 |
| Dialogue Between Parent | 0.307208 |
| Wolfelt A | 0.31079 |
| Hemisphere Publishing Corporation | 0.30651 |
| siguientes preguntas | 0.304497 |
| Corr CA | 0.321186 |
| aflicción anticipatoria | 0.975865 |
| Do We Tell | 0.306573 |
| baja autoestima | 0.304526 |
| Aflicción normalLa | 0.370032 |
| Aflicción crónica | 0.366865 |
| Instituto Nacional | 0.309451 |
| cansancio extremo | 0.305043 |
| GP Putnam Sons | 0.306438 |
| Mourning Children | 0.305247 |
| familiar cercano | 0.304362 |
| When Someone Dies | 0.30744 |
| siguientes libros | 0.304582 |
| Tiffault BW | 0.304106 |
| años todavÃa | 0.304515 |
| Help Children Participate | 0.307506 |
| TCC ayuda | 0.305556 |
| religión ayuda | 0.304338 |
| muerte ayuda | 0.319844 |
|
| desarrollo edad comprensión | 0.306829 |
| Remember Someone You | 0.30677 |
| muerte expresiones | 0.319738 |
| PDQ Aflicción | 0.353557 |
| conversación).El tratamiento | 0.305805 |
| aflicción anticipatoria ayuda | 0.436499 |
| Publishing Company | 0.310219 |
| National Cancer Institute | 0.305834 |
| anticipatoriaLa aflicción anticipatoria | 0.37147 |
| siguientes riesgos | 0.304531 |
| New York | 0.346791 |
| Children Mourning | 0.305247 |
| siguientes factores | 0.316168 |
| Physician Data Query | 0.319434 |
| MÃnima reacción | 0.30471 |
| Mountain Rainbow Publications | 0.306521 |
| Talking About Death | 0.30672 |
| Springer Publishing Company | 0.306508 |
| Children Cope with | 0.321223 |
| Parent Dies | 0.311854 |
| Tenth Good Thing | 0.306668 |
| Helping Children Cope | 0.321422 |
| Helping Children Understand | 0.308268 |
| Accelerated Development | 0.311496 |
|
CLICK HERE |
| 1894 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pulmón de células no pequeñas (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células no pequeñas. |
| radiocirugÃa estereotáctica | 0.521736 |
| cuáles ganglios | 0.544229 |
| estadio iv | 0.535294 |
| pequeño corte | 0.516426 |
| sustancia llamada fcev | 0.511226 |
| faja ajustadora | 0.518847 |
| pequeña cantidad | 0.570347 |
| Silbido respiratorio | 0.522024 |
| cáncer.ampliar broncoscopia | 0.521373 |
| gen alk | 0.51503 |
| cáncer.ampliar mediastinoscopÃa | 0.517089 |
| células normales.ampliar exploración | 0.600106 |
| cuerpo.ampliar radiografÃa | 0.522592 |
| estadios ia | 0.514018 |
| rayos x | 0.552576 |
| estadio ib | 0.557189 |
| estadio ia | 0.556394 |
| enlace drugs approved | 0.531609 |
| ondas sonoras | 0.51647 |
| Non-Small Cell Lung | 0.531866 |
| células t | 0.528626 |
| vÃas respiratorias | 0.808836 |
|
| carcinoma epidermoide | 0.525518 |
| numerosos ensayos | 0.516625 |
| pecho.ampliar biopsia | 0.526618 |
| estadios iia | 0.515213 |
| estadio iiia | 0.625519 |
| determinadas células | 0.530359 |
| antecedentes familiares | 0.518918 |
| alta potencia | 0.516655 |
| estadio iia | 0.557019 |
| tirosina cinasa | 0.692486 |
| Cell Lung Cancer | 0.531364 |
| siguientes sitios | 0.51534 |
| siguientes situaciones | 0.666362 |
| ecografÃa ayuda | 0.515534 |
| principal factor | 0.576142 |
| áreas.ampliar biopsia | 0.52208 |
| siguientes formas | 0.529859 |
| bronquiolos.ampliar anatomÃa | 0.52368 |
| siguientes sumarios | 0.532291 |
| siguientes pruebas | 0.527678 |
| vasos sanguÃneos | 0.979174 |
|
CLICK HERE |
| 1951 |
National Cancer Institute |
Html |
es |
Tratamiento de los síndromes mielodisplásicos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los síndromes mielodisplásicos. |
| siguientes procedimientos | 0.408317 |
| displasia multilinaje | 0.404818 |
| células madre | 0.698581 |
| leucemia aguda | 0.40611 |
| sÃndromes mielodisplásicos | 0.99284 |
| hueso compacto | 0.416921 |
| neoplasias mieloides | 0.402645 |
| plaquetas maduras | 0.410918 |
| célula madre mieloide | 0.437557 |
| National Cancer Institute | 0.402744 |
| siguientes riesgos | 0.401921 |
| vitamina b12 | 0.403995 |
|
| Instituto Nacional | 0.404912 |
| PDQ Tratamiento | 0.439829 |
| célula madre linfoide | 0.43173 |
| vidrio piezas | 0.403146 |
| neoplasias mielodisplásicas | 0.404775 |
| displasia unilinaje | 0.404747 |
| Physician Data Query | 0.410747 |
| cáncer.ampliar trasplante | 0.403337 |
| leucemia mieloide aguda | 0.59748 |
| célula madre | 0.50311 |
| células sanguÃneas maduras | 0.465531 |
| siguientes pruebas | 0.40454 |
|
CLICK HERE |
| 2025 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer colorrectal (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre las pruebas que se usan para detectar el cáncer colorrectal. |
| PDQ Exámenes | 0.849253 |
| Physician Data Query | 0.949845 |
| sigmoidoscopia causa | 0.801378 |
| tubo recolector | 0.784476 |
| Estados Unidos | 0.979222 |
| riesgos.Los exámenes | 0.85829 |
| cuerpo).ampliar anatomÃa | 0.797555 |
| prevención revisa | 0.744583 |
| radiografÃas llamada | 0.774966 |
|
| PDQ Prevención | 0.956837 |
| pequeño aumento | 0.790999 |
| siguientes exámenes | 0.980519 |
| información ayuda | 0.751125 |
| National Cancer Institute | 0.760892 |
| siguientes riesgos | 0.742979 |
| siguientes sumarios | 0.885224 |
| Instituto Nacional | 0.814155 |
|
CLICK HERE |
| 3454 |
National Cancer Institute |
Html |
es |
Grados de comprobación científica de los estudios de terapias integrales, alternativas y complementarias en seres humanos con cáncer (PDQ®)–Versión para profesionales de salud |
Información acerca de cómo evaluar la solidez de los datos probatorios obtenidos de los estudios de investigación sobre terapias integrales, alternativas y complementarias en seres humanos con cáncer. |
| Visuals Online | 0.6561 |
| grupo control | 0.658003 |
| Physician Data Query | 0.707803 |
| distintos tipos | 0.676327 |
| mejores casos— | 0.670195 |
| valoración indirectos | 0.860816 |
| tratamiento versus muerte | 0.748944 |
|
| National Cancer Institute | 0.697449 |
| personas ayuda | 0.673043 |
| siguientes riesgos | 0.659857 |
| mejores casos | 0.807578 |
| versus muerte | 0.798627 |
| Instituto Nacional | 0.960893 |
|
CLICK HERE |
| 3551 |
National Cancer Institute |
Html |
en |
Cancer Statistics |
Basic information about cancer statistics in the U.S. and how they are used to understand the impact of cancer on society and to develop strategies that address the challenges that cancer poses. |
| cancer statistics | 0.699332 |
| major impact | 0.569457 |
| new screening test | 0.610486 |
| United States | 0.848591 |
| Asian/Pacific Islander women | 0.623563 |
| cancer death rate | 0.734611 |
| cancer deaths | 0.662668 |
| thyroid cancer | 0.618391 |
| SEER program website | 0.613262 |
| renal pelvis cancer | 0.675159 |
| population-based cancer registries | 0.661094 |
| African American men | 0.620993 |
| number | 0.579668 |
| new cancer cases | 0.74726 |
| American Cancer Society | 0.655347 |
| pancreatic cancer | 0.619919 |
| bladder cancer | 0.619451 |
| cancer-related deaths | 0.575865 |
| average age | 0.568157 |
| individual cancer types | 0.652597 |
| North American Association | 0.605716 |
| racial/ethnic group | 0.570832 |
| cancer care | 0.615369 |
| cancer diagnosis | 0.664799 |
|
| breast cancer | 0.617639 |
| rectum cancer | 0.622513 |
| large groups | 0.569141 |
| risk factor | 0.614571 |
| U.S. population | 0.610565 |
| people | 0.571698 |
| statistical trends | 0.613522 |
| age-adjusted mortality | 0.572947 |
| prostate cancer | 0.619132 |
| bronchus cancer | 0.62075 |
| Central Cancer Registries | 0.654709 |
| cancer survivors | 0.603772 |
| cancer mortality | 0.652323 |
| policy makers | 0.566593 |
| Understanding Cancer Prognosis | 0.676403 |
| endometrial cancer | 0.620993 |
| cancer | 0.951216 |
| new cases | 0.679157 |
| cancer incidence | 0.694185 |
| cancer death rates | 0.665983 |
| SEER Cancer Statistics | 0.665479 |
| overall cancer death | 0.735155 |
| cancer rates | 0.609223 |
|
CLICK HERE |
| 15774 |
National Cancer Institute |
Html |
en |
Cancer Clinical Trials API |
Access NCI-supported cancer clinical trials information through an application programming interface (API). |
| IND/IDE information | 0.322332 |
| search tools | 0.31747 |
| initial working piece | 0.395837 |
| clinical trial information | 0.444384 |
| application programming interface | 0.438002 |
| developers | 0.217415 |
| CTRP information | 0.321432 |
| questions | 0.217374 |
| Clinical Trials Reporting | 0.43587 |
| NCI-supported cancer | 0.32979 |
| biomarker data | 0.321606 |
| feedback | 0.238876 |
| clinical trial search | 0.427355 |
| database | 0.218238 |
| academia | 0.222589 |
| NCI-specific Data Table | 0.401719 |
| individual communities | 0.317208 |
| contact | 0.217352 |
| large amounts | 0.326709 |
| clinical trials | 0.959644 |
| family members | 0.316516 |
| summary | 0.217584 |
|
| community—advocacy groups | 0.318407 |
| ct-api-support@nih.gov. | 0.306404 |
| Clinical Trials API | 0.843331 |
| beta version | 0.313025 |
| https://clinicaltrialsapi.cancer.gov | 0.217378 |
| meaningful ways | 0.325497 |
| regulatory information | 0.322729 |
| common language | 0.320268 |
| patients | 0.239672 |
| Documentation | 0.217429 |
| digital platforms | 0.317392 |
| public web | 0.304451 |
| help | 0.217404 |
| better search results | 0.40957 |
| cancer clinical trials | 0.743102 |
| IRB approval details | 0.415735 |
| accrual information | 0.335388 |
| oncologists | 0.229097 |
| integrations | 0.227372 |
| providers | 0.219039 |
| Trials Beta API | 0.505116 |
|
CLICK HERE |
| 16829 |
National Cancer Institute |
Html |
en |
Cancer Driver Discovery Program |
null |
| large number | 0.638311 |
| tumor biology | 0.66038 |
| rare driver events | 0.719635 |
| comprehensive genomic characterization | 0.740363 |
| genomic analyses | 0.633135 |
| patient responses | 0.721865 |
| tumor tissues | 0.638276 |
| additional driver mutations | 0.771411 |
| lung cancer | 0.952268 |
| statistical models | 0.628862 |
| statistical power | 0.629897 |
| cancer genomics | 0.65394 |
| recurrent mutations | 0.655852 |
| patients | 0.702611 |
| Genomic Data Commons | 0.762952 |
| clinical trial N0147 | 0.722969 |
| Lung Cancer project | 0.792668 |
| molecular causes | 0.642033 |
| oncogenic process | 0.640394 |
| public health impact | 0.739202 |
| epidermal growth factor | 0.708102 |
| tumor types | 0.658904 |
| Cancer Driver Discovery | 0.8155 |
| DNA sequencing | 0.651327 |
| Cancer Research UK | 0.776689 |
|
| RNA sequence | 0.636519 |
| associated follow-up information | 0.721592 |
| ovarian cancers | 0.639935 |
| better treatment options | 0.776737 |
| clinical outcomes | 0.638824 |
| Foundation Lung Cancer | 0.793933 |
| intratumoral heterogeneity | 0.742723 |
| deeper characterization | 0.652385 |
| TRACERx collaborators | 0.637079 |
| NCI-funded clinical trial | 0.73112 |
| Genome Characterization Pipeline | 0.748856 |
| driver mutations | 0.919706 |
| St. James | 0.824605 |
| Tracking Cancer Evolution | 0.775958 |
| CCG | 0.851349 |
| colon cancer | 0.744767 |
| lung adenocarcinoma | 0.669686 |
| TRACERx study | 0.634122 |
| total RNA sequencing | 0.961331 |
| Cancer Genome Atlas | 0.832019 |
| chemotherapy regimen | 0.639583 |
| particular lung cancer | 0.807795 |
| Central Cancer Treatment | 0.762707 |
| genome sequencing | 0.685209 |
|
CLICK HERE |